<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIGITEK- digoxin tablet </strong><br>Mylan Institutional Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DIGITEK<span class="Sup">®</span> (digoxin tablets) safely and effectively.  See full prescribing information for DIGITEK<span class="Sup">® </span>(digoxin tablets). <br><br>DIGITEK<span class="Sup">®</span> (digoxin tablets, USP) for oral use <br>Initial U.S. Approval: 1954</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Digoxin is a cardiac glycoside indicated for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in adults. (<a href="#ID_08ec0315-5903-4edf-91de-c628a96c3148">1.1</a>)</dd>
<dt>•</dt>
<dd>Increasing myocardial contractility in pediatric patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#ID_8621e136-068c-45b4-80a7-62b8621bfae7">1.2</a>)</dd>
<dt>•</dt>
<dd>Control of resting ventricular rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> in adults. (<a href="#ID_a7459062-7b4a-42b4-9130-c0d2123ac695">1.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">DIGITEK<span class="Sup">®</span> (digoxin tablet) dose is based on patient-specific factors (age, lean body weight, renal function, etc.). See full prescribing information. Monitor for toxicity and therapeutic effect. (<a href="#ID_3a08295e-b86d-4944-9d08-904772ea0931">2</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"><span class="Italics">Tablets: </span>125 mcg (0.125 mg) and 250 mcg (0.25 mg) scored (<a href="#ID_9aa5e3d1-1e1b-442a-9804-1df977f98ff4">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span>. (<a href="#ID_cc278257-578d-4288-8b1e-97d33f27f3db">4</a>)</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to digoxin or other forms of digitalis. (<a href="#ID_cc278257-578d-4288-8b1e-97d33f27f3db">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Risk of rapid ventricular response leading to <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> in patients with AV accessory pathway. (<a href="#ID_6dc6ce7c-b554-457b-a2ba-737102b4c0cb">5.1</a>)</dd>
<dt>•</dt>
<dd>Risk of advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> in patients with sinus node disease and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. (<a href="#ID_eddb25b8-8e0f-4775-a3eb-e055db5f7b64">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin toxicity</span>: Indicated by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. Advanced age, low body weight, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and electrolyte abnormalities predispose to toxicity. (<a href="#ID_d579c1fd-e9ed-495c-99cf-c23f68615da2">5.3</a>)</dd>
<dt>•</dt>
<dd>Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> during electrical cardioversion. (<a href="#ID_0ad90b20-3369-4316-b702-176ec10492fa">5.4</a>)</dd>
<dt>•</dt>
<dd>Not recommended in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. (<a href="#ID_16988984-9c0b-4c48-9713-bb45d8356fbc">5.5</a>)</dd>
<dt>•</dt>
<dd>Avoid digoxin in patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>. (<a href="#ID_2a97f4aa-2f0f-46e2-b548-9483bdae04fd">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The overall incidence of adverse reactions with digoxin has been reported as 5% to 20%, with 15% to 20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events. (<a href="#ID_98d8d00e-b938-4dd3-8de9-36d65a4a79ba">6.1</a>).<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">PGP Inducers/Inhibitors: </span>Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (<a href="#ID_0e1553ad-334f-44e2-bddb-6a3596b9065f">7.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Many Drug Interaction: </span>The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information. (<a href="#ID_901cda87-7b22-4f20-836c-35800ff2962b">7.3</a>, <a href="#ID_78bc1561-facf-4be6-a2f0-83af1220b806">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Pregnant Patients: </span>It is unknown whether use during pregnancy can cause fetal harm. (<a href="#ID_55044dcd-0ede-430e-bc53-02e40c9877ec">8.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Pediatric Patients:</span> Newborn infants display variability in tolerance to digoxin. (<a href="#ID_462b87b6-03ac-4b4c-beca-d413c4b2abac">8.4</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Geriatric Patients: </span>Consider renal function in dosage selection and carefully monitor for side effects. (<a href="#ID_5d5f58db-8a0c-4e0a-b589-a59ddfefd731">8.5</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span>Digoxin is excreted by the kidneys. Consider renal function during dosage selection. (<a href="#ID_8a9b1193-77e4-4ac5-829c-ef7e75509e0d">8.6</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Adults</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Pediatric Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in Adults</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Important Dosing and Administration Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Loading Dosing Regimen in Adults and Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance Dosing in Adults and Pediatric Patients over 10 Years Old</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance Dosing in Pediatric Patients less than 10 Years Old</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Monitoring to Assess Safety, Efficacy and Therapeutic Blood Levels</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Switching from Intravenous Digoxin to Oral Digoxin</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular Fibrillation</span> in Patients with Accessory AV Pathway (Wolff-Parkinson- White Syndrome)</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">Sinoatrial Block</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> during Electrical Cardioversion</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Risk of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> in Patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">Vasoconstriction</span> in Patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac Output</span> in Patients with Preserved Left Ventricular Systolic Function</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Reduced Efficacy in Patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Altered Response in <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span> and Hypermetabolic States</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 P-Glycoprotein (PGP) Inducers/Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Pharmacokinetic Drug Interactions</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potentially Significant Pharmacodynamic Drug Interactions</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and Symptoms in Adults and Children</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Treatment</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Chronic Atrial Fibrillation</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_f265f15e-b18b-4d91-8202-4f811396bc2e"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08ec0315-5903-4edf-91de-c628a96c3148"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Adults</h2>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets) is indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in adults. DIGITEK<span class="Sup">®</span> (digoxin tablets) increases left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and improves <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> symptoms as evidenced by improved exercise capacity and decreased <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care, while having no effect on mortality. Where possible, DIGITEK<span class="Sup">®</span> (digoxin tablets) should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8621e136-068c-45b4-80a7-62b8621bfae7"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Pediatric Patients</h2>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets) increases myocardial contractility in pediatric patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7459062-7b4a-42b4-9130-c0d2123ac695"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in Adults</h2>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets) is indicated for the control of ventricular response rate in adult patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_3a08295e-b86d-4944-9d08-904772ea0931"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_285cf51f-2424-4646-9efd-60593adc1d23"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Important Dosing and Administration Information</h2>
<p class="First">In selecting a DIGITEK<span class="Sup">®</span> (digoxin tablets) dosing regimen, it is important to consider factors that affect digoxin blood levels (e.g., body weight, age, renal function, concomitant drugs) since toxic levels of digoxin are only slightly higher than therapeutic levels. Dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired <span class="Bold">or </span>initiated with maintenance dosing without a loading dose.</p>
<p>Consider interruption or reduction in digoxin dose prior to electrical cardioversion <span class="Italics">[see <a href="#ID_0ad90b20-3369-4316-b702-176ec10492fa">Warnings and Precautions (5.4)</a>].</span></p>
<p>Use digoxin solution to obtain the appropriate dose in infants, young pediatric patients or patients with very low body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0397773d-4c80-4496-8468-9f71f09b4cbd"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Loading Dosing Regimen in Adults and Pediatric Patients</h2>
<p class="First">For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then ¼ the loading dose every 6 to 8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended loading dose is displayed in Table 1.</p>
<a name="_RefID0EVAAE"></a><table width="100%">
<caption><span>Table 1. Recommended DIGITEK<span class="Sup">®</span> (digoxin tablets) Oral Loading Dose</span></caption>
<col width="46%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Total Oral Loading Dose (mcg/kg)</span><br>Administer half the total loading dose initially, then<br>¼ the loading dose every 6 to 8 hours twice</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> 5 years to 10 years</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 to 45</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"> Adults and pediatric patients over 10 years</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 to 15</p></td>
</tr>
</tbody>
</table>
<p>mcg = micrograms</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8a2e598-ceff-4245-ba32-9b085ebb7d60"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance Dosing in Adults and Pediatric Patients over 10 Years Old</h2>
<p class="First">The maintenance dose is based on lean body weight, renal function, age and concomitant products <span class="Italics">[see <a href="#ID_78bc1561-facf-4be6-a2f0-83af1220b806">Clinical Pharmacology (12.3)</a>].</span></p>
<p>The recommended <span class="Bold">starting</span> maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Doses may be increased every 2 weeks according to clinical response, serum drug levels and toxicity.</p>
<a name="_RefID0E3CAE"></a><table width="100%">
<caption><span>Table 2.  Recommended Starting DIGITEK<span class="Sup">®</span> (digoxin tablets) Maintenance Dosage in Adults and Pediatric Patients over 10 Years Old</span></caption>
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Total Oral Maintenance Dose, mcg/kg/day </span><br><span class="Bold">(given once daily)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"> Adults and pediatric patients over 10 years</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.4 to 5.1</p></td>
</tr>
</tbody>
</table>
<p>mcg = micrograms</p>
<p>Table 3 provides the recommended (once daily) maintenance dose for adults and pediatric patients over 10 years old (to be given once daily) according to lean body weight and renal function. The doses are based on studies in adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Alternatively, the maintenance dose may be estimated by the following formula (peak body stores lost each day through elimination):</p>
<p>Total Maintenance Dose = Loading Dose (i.e., Peak Body Stores) x % Daily Loss/100<br>(% Daily Loss = 14 + Creatinine clearance/5)</p>
<p>Reduce the dose of DIGITEK<span class="Sup">®</span> (digoxin tablets) in patients whose lean weight is an abnormally small fraction of their total body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> because of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<a name="_RefID0EGEAE"></a><table width="100%">
<caption><span>Table 3.  Recommended Maintenance Dose (in micrograms given once daily) of DIGITEK<span class="Sup">®</span> (digoxin tablets) in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Function<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="19%">
<col width="17%">
<col width="15%">
<col width="6%">
<col width="6%">
<col width="6%">
<col width="6%">
<col width="6%">
<col width="6%">
<col width="10%">
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Doses are rounded to the nearest dose possible using whole and/or half DIGITEK<span class="Sup">®</span> (digoxin tablets) tablets. Recommended doses approximately 30% lower than the calculated dose are designated with an *. Monitor digoxin levels in patients receiving these initial doses and increase dose if needed.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>
<span class="Italics">For adults</span>, creatinine clearance was corrected to 70 kg body weight or 1.73 m<span class="Sup">2</span> body surface area. If only serum creatinine concentrations (Scr) are available, a corrected Ccr may be estimated in men as (140 – Age)/Scr. For women, this result should be multiplied by 0.85. <span class="Italics">For pediatric </span>patients, the modified Schwartz equation may be used. The formula is based on height in cm and Scr in mg/dL where k is a constant. Ccr is corrected to 1.73 m<span class="Sup">2</span> body surface area. During the first year of life, the value of k is 0.33 for pre-term babies and 0.45 for term infants. The k is 0.55 for pediatric patients and adolescent girls and 0.7 for adolescent boys.GFR (mL/min/1.73 m<span class="Sup">2</span>) = (k x Height)/Scr</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>The doses listed assume average body composition.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>If no loading dose administered.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First"><span class="Bold">Corrected Creatinine Clearance</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="8"><p class="First">Lean Body Weight<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First">Number<br>of Days<br>Before<br>Steady<br>State<br>Achieved<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">kg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">40</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">50</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">60</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">70</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">80</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">90</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">100</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">lb</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">110</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">132</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">154</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">176</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">198</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">220</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">437.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">90 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">437.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">437.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">437.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">500</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_79b75f49-06b2-4c91-9358-f594f5238ecb"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance Dosing in Pediatric Patients less than 10 Years Old</h2>
<p class="First">The starting maintenance dose for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in pediatric patients less than 10 years old is based on lean body weight, renal function, age and concomitant products <span class="Italics">[see <a href="#ID_78bc1561-facf-4be6-a2f0-83af1220b806">Clinical Pharmacology (12.3)</a>].</span> The recommended <span class="Bold">starting </span>maintenance dose for pediatric patients between 5 and 10 years old is given in Table 4. These recommendations assume the presence of normal renal function.</p>
<a name="_RefID0EC1AE"></a><table width="100%">
<caption><span>Table 4.  Recommended Starting DIGITEK<span class="Sup">®</span> (digoxin tablets) Oral Maintenance Dosage in Pediatric Patients between 5 and 10 Years Old</span></caption>
<col width="46%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Oral Maintenance Dose,</span><br><span class="Bold">mcg/kg/dose</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">5 years to 10 years</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.2 to 6.4 <span class="Bold">Twice daily</span></p></td>
</tr>
</tbody>
</table>
<p>Table 5 provides average daily maintenance dose requirements for pediatric patients between 5 and 10 years old (to be given twice daily) with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on age, lean body weight and renal function.</p>
<a name="_RefID0EG2AE"></a><table width="100%">
<caption><span>Table 5. Recommended Maintenance Dose (in micrograms given twice daily) of DIGITEK<span class="Sup">®</span> (digoxin tablets) in Pediatric Patients between 5 and 10 Years of Age* Based upon Lean Body Weight and Renal Function<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>, <a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></span></caption>
<col width="17%">
<col width="17%">
<col width="17%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="14%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Recommended are doses to be given twice daily.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>The doses are rounded to the nearest dose possible using whole and/or half digoxin tablets. Recommended doses approximately 30 percent lower than the calculated dose are designated with an *. Monitor digoxin levels in patients receiving these initial doses and increase dose if needed.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>The modified Schwartz equation may be used to estimate creatinine clearance. See footnote b under Table 3. </dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd>If no loading dose administered.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First"><span class="Bold">Corrected</span><br><span class="Bold">Creatinine</span><br><span class="Bold">Clearance</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="6"><p class="First">Lean Body Weight</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First">Number of<br>Days<br>Before<br>Steady<br>State<br>Achieved<a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">kg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">20</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">30</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">40</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">50</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">60</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">lb</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">66</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">110</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">132</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">90 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 mL/min</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">187.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">312.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2e3812e1-f53c-4969-823e-79519a4c7295"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Monitoring to Assess Safety, Efficacy and Therapeutic Blood Levels</h2>
<p class="First">Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> and clinical response. Adjust dose based on toxicity, efficacy and blood levels.</p>
<p>Serum digoxin levels &lt; 0.5 ng/mL have been associated with diminished efficacy, while levels above 2 ng/mL have been associated with increased toxicity without increased benefit.</p>
<p>Interpret the serum digoxin concentration in the overall clinical context, and do not use an isolated measurement of serum digoxin concentration as the basis for increasing or decreasing the DIGITEK<span class="Sup">®</span> (digoxin tablets) dose. Serum digoxin concentrations may be falsely elevated by endogenous digoxin-like substances <span class="Italics">[see <a href="#ID_2a2707bd-774c-4f04-89d1-90301af06cd5">Drug Interactions (7.4)</a>].</span> If the assay is sensitive to these substances, consider obtaining a baseline digoxin level before starting DIGITEK<span class="Sup">®</span> (digoxin tablets) and correct post-treatment values by the reported baseline level.</p>
<p>Obtain serum digoxin concentrations just before the next scheduled DIGITEK<span class="Sup">®</span> (digoxin tablets) dose or at least 6 hours after the last dose. The digoxin concentration is likely to be 10% to 25% lower when sampled right before the next dose (24 hours after dosing) compared to sampling 8 hours after dosing (using once-daily dosing). However, there will be only minor differences in digoxin concentrations using twice daily dosing whether sampling is done at 8 or 12 hours after a dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a0d51621-c5d4-4c80-a11f-79aa449f4376"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Switching from Intravenous Digoxin to Oral Digoxin</h2>
<p class="First">When switching from intravenous to oral digoxin formulations, make allowances for differences in bioavailability when calculating maintenance dosages (see Table 6).</p>
<a name="_RefID0EFOAG"></a><table width="100%">
<caption><span>Table 6.  Comparison of the Systemic Availability and Equivalent Doses of Oral and Intravenous DIGITEK<span class="Sup">®</span> (digoxin tablets)</span></caption>
<col width="38%">
<col width="32%">
<col width="9%">
<col width="7%">
<col width="7%">
<col width="7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Absolute Bioavailability</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Equivalent Doses (mcg)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> DIGITEK<span class="Sup">®</span> (digoxin tablets) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60% to 80%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">500</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"> Digoxin Intravenous Injection</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">200</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">400</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_9aa5e3d1-1e1b-442a-9804-1df977f98ff4"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">The 125 mcg (0.125 mg) tablets are yellow round, scored, slope-faced tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">145</span> below the score on one side of the tablet and blank on the other side. </p>
<p>The 250 mcg (0.25 mg) tablets are white round, scored, slope-faced tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">147</span> below the score on one side of the tablet and blank on the other side. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_cc278257-578d-4288-8b1e-97d33f27f3db"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets) is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span> <span class="Italics">[see <a href="#ID_6dc6ce7c-b554-457b-a2ba-737102b4c0cb">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to digoxin (reactions seen include unexplained <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the mouth, lips or throat or a difficulty in breathing). A <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to other digitalis preparations usually constitutes a contraindication to digoxin.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_f5264a6d-9a10-4ee0-8e09-9c5286625b36"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6dc6ce7c-b554-457b-a2ba-737102b4c0cb"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular Fibrillation</span> in Patients with Accessory AV Pathway (Wolff-Parkinson- White Syndrome)</h2>
<p class="First">Patients with Wolff-Parkinson-White syndrome who develop <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are at high risk of <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. Treatment of these patients with digoxin leads to greater slowing of conduction in the atrioventricular node than in accessory pathways, and the risks of rapid ventricular response leading to <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> are thereby increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eddb25b8-8e0f-4775-a3eb-e055db5f7b64"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">Sinoatrial Block</span></h2>
<p class="First">Digoxin may cause severe <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span> particularly in patients with preexisting sinus node disease and may cause advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> in patients with preexisting incomplete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. Consider insertion of a pacemaker before treatment with digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d579c1fd-e9ed-495c-99cf-c23f68615da2"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span></h2>
<p class="First">Signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> [first-degree, second-degree (<span class="product-label-link" type="condition" conceptid="318448" conceptname="Second degree atrioventricular block">Wenckebach</span>) or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> (including <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>); <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> with block; <span class="product-label-link" type="condition" conceptid="4175473" conceptname="Atrioventricular dissociation">AV dissociation</span>; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span> or <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">trigeminy</span>); <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>]. Toxicity is usually associated with digoxin levels &gt; 2 ng/ml although symptoms may also occur at lower levels. Low body weight, advanced age or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may predispose to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. Obtain serum digoxin levels in patients with signs or symptoms of digoxin therapy and interrupt or adjust dose if necessary <span class="Italics">[see <a href="#ID_d6ccd717-556a-452d-88a3-982bfc8e4b9e">Adverse Reactions (6)</a> and <a href="#ID_35a982d8-2384-40e2-a524-d998adfa06c8">Overdosage (10)</a>]. </span>Assess serum electrolytes and renal function periodically.</p>
<p>The earliest and most frequent manifestation of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> in infants and children is the appearance of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. In children, the use of digoxin may produce any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. The most common are conduction disturbances or supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> (with or without block) and junctional (nodal) <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> are less common. <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> may be a sign of impending digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, especially in infants, even in the absence of first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or alteration in cardiac conduction that develops in a child taking digoxin should initially be assumed to be a consequence of digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p>Given that adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have some symptoms in common with <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>, it may be difficult to distinguish <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> from <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Misidentification of their etiology might lead the clinician to continue or increase digoxin dosing, when dosing should actually be suspended. When the etiology of these signs and symptoms is not clear, measure serum digoxin levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0ad90b20-3369-4316-b702-176ec10492fa"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> during Electrical Cardioversion</h2>
<p class="First">It may be desirable to reduce the dose of or discontinue digoxin for 1 to 2 days prior to electrical cardioversion of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to avoid the induction of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, but physicians must consider the consequences of increasing the ventricular response if digoxin is decreased or withdrawn. If <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> is suspected, elective cardioversion should be delayed. If it is not prudent to delay cardioversion, the lowest possible energy level should be selected to avoid provoking <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16988984-9c0b-4c48-9713-bb45d8356fbc"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Risk of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> in Patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> </h2>
<p class="First">Digoxin is not recommended in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> because digoxin may increase myocardial oxygen demand and lead to <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2a97f4aa-2f0f-46e2-b548-9483bdae04fd"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">Vasoconstriction</span> in Patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> </h2>
<p class="First">Digoxin can precipitate <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and may promote production of pro-inflammatory cytokines; therefore, avoid use in patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49b554d8-df19-45f3-992d-f227ca79797a"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac Output</span> in Patients with Preserved Left Ventricular Systolic Function</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> associated with preserved left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> may experience decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> with use of digoxin. Such disorders include <span class="product-label-link" type="condition" conceptid="4190773" conceptname="Restrictive cardiomyopathy">restrictive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>, amyloid heart disease and <span class="product-label-link" type="condition" conceptid="312927" conceptname="Acute cor pulmonale">acute cor pulmonale</span>. Patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">idiopathic hypertrophic subaortic stenosis</span> may have worsening of the outflow obstruction due to the inotropic effects of digoxin. Patients with amyloid heart disease may be more susceptible to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> at therapeutic levels because of an increased binding of digoxin to extracellular amyloid fibrils.</p>
<p>Digoxin should generally be avoided in these patients, although it has been used for ventricular rate control in the subgroup of patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20dd9065-3905-48c7-ae24-f6c071a22e62"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Reduced Efficacy in Patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> can nullify the effects of digoxin in humans; thus, digoxin may be ineffective until serum calcium is restored to normal. These interactions are related to the fact that digoxin affects contractility and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> of the heart in a manner similar to that of calcium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9024d991-ab0f-4ac3-8ee7-30d35c126c00"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Altered Response in <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span> and Hypermetabolic States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> may reduce the requirements for digoxin.</p>
<p><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> and/or <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span> resulting from hypermetabolic or hyperdynamic states (e.g., <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or arteriovenous shunt) are best treated by addressing the underlying condition. <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">Atrial arrhythmias</span> associated with hypermetabolic states are particularly resistant to digoxin treatment. Patients with <span class="product-label-link" type="condition" conceptid="434620" conceptname="Beriberi">beri beri</span> heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_d6ccd717-556a-452d-88a3-982bfc8e4b9e"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are included in more detail in the Warnings and Precautions section of the label:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span> <span class="Italics">[see <a href="#ID_6dc6ce7c-b554-457b-a2ba-737102b4c0cb">Warnings and Precautions (5.1</a>, <a href="#ID_eddb25b8-8e0f-4775-a3eb-e055db5f7b64">5.2)</a>]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span> <span class="Italics">[see <a href="#ID_d579c1fd-e9ed-495c-99cf-c23f68615da2">Warnings and Precautions (5.3)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_98d8d00e-b938-4dd3-8de9-36d65a4a79ba"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In general, the adverse reactions of digoxin are dose dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when digoxin is used within the recommended dose range, is maintained within the therapeutic serum concentration range, and when there is careful attention to concurrent medications and conditions.</p>
<p>In the DIG trial (a trial investigating the effect of digoxin on mortality and morbidity in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), the incidence of hospitalization for suspected <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> was 2% in patients taking digoxin compared to 0.9% in patients taking placebo <span class="Italics">[see <a href="#ID_63bb3b7f-2e4e-4ab9-8fc9-3adec10f3c86">Clinical Studies (14.1)</a>]</span>.</p>
<p>The overall incidence of adverse reactions with digoxin has been reported as 5% to 20%, with 15% to 20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4e9490e7-1852-4fb6-81d2-0d652a555228"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Gastrointestinal</span></h3>
<p class="First">In addition to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the use of digoxin has been associated with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">intestinal ischemia</span> and hemorrhagic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the intestines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c02d7252-3e74-4d4e-8542-23c14d40e0e4"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">CNS</span></h3>
<p class="First">Digoxin can cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and mental disturbances (such as <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cb29c70d-6338-4272-9a99-1d0e1ad7a7d6"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Other</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> has been occasionally observed following the prolonged use of digoxin. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span> and other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been rarely observed. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_4e3cda95-2607-41c6-83b2-97ae69a3d087"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0e1553ad-334f-44e2-bddb-6a3596b9065f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 P-Glycoprotein (PGP) Inducers/Inhibitors</h2>
<p class="First">Digoxin is a substrate of P-glycoprotein. Drugs that induce or inhibit P-glycoprotein in intestine or kidney have the potential to alter digoxin pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_369964ad-4efa-40b5-87cf-732c12221551"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Pharmacokinetic Drug Interactions</h2>
<table width="100%">
<col width="18%">
<col width="26%">
<col width="17%">
<col width="39%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Digoxin concentrations increased &gt; 50%</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Digoxin Serum Concentration Increase</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Digoxin AUC Increase</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Recommendations</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Amiodarone </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" rowspan="14"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30% to 50% or by modifying the dosing frequency and continue monitoring.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Captopril </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">58%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">39%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Clarithromycin </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Dronedarone </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">150%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Gentamicin </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">129% to 212%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Erythromycin </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Itraconazole </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nitrendipine </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Propafenone </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60% to 270%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Quinidine </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ranolazine </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ritonavir </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Tetracycline </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Verapamil </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50% to 75%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Digoxin concentrations increased &lt; 50%</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Atorvastatin </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15%</p></td>
<td class="Botrule Lrule Rrule" rowspan="13"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15% to 30% or by modifying the dosing frequency and continue monitoring.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Carvedilol </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Diltiazem </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Indomethacin </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nefazodone </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nifedipine </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Propantheline </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Quinine </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Saquinavir </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">49%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Spironolactone </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Telmisartan </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20% to 49%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Tolvaptan </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Trimethoprim </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22% to 28%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Digoxin concentrations increased, but magnitude is unclear</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="3"><p class="First">Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, quinine, rabeprazole</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary. </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Digoxin concentrations decreased</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="3"><p class="First">Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’sWort, sucralfate, sulfasalazine</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and increase digoxin dose by approximately 20% to 40% as necessary.</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">No significant Digoxin exposure changes</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" colspan="3"><p class="First">Please refer to section 12 for a complete list of drugs which were studied but reported no significant changes on digoxin exposure.</p></td>
<td class="Botrule Lrule Rrule"><p class="First">No additional actions are required.</p></td>
</tr>
</tbody>
</table>
<p class="First">NA – Not available/reported</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_901cda87-7b22-4f20-836c-35800ff2962b"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potentially Significant Pharmacodynamic Drug Interactions</h2>
<p class="First">Because of considerable variability of <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>, the dosage of digoxin should be individualized when patients receive these medications concurrently.</p>
<table width="100%">
<col width="24%">
<col width="17%">
<col width="60%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> Drugs that Affect Renal Function</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDS], COX-2 inhibitors may impair the excretion of digoxin.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Antiarrthymics</p></td>
<td class="Botrule Lrule"><p class="First">Dofetilide</p></td>
<td class="Botrule Rrule"><p class="First">Concomitant administration with digoxin was associated with a higher rate of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule"><p class="First">Sotalol</p></td>
<td class="Botrule Rrule"><p class="First">Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span>, in patients receiving digoxin.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule"><p class="First">Dronedarone</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients receiving digoxin.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Parathyroid Hormone Analog</p></td>
<td class="Botrule Lrule"><p class="First">Teriparatide</p></td>
<td class="Botrule Rrule"><p class="First">Sporadic case reports have suggested that <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may predispose patients to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Teriparatide transiently increases serum calcium.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Thyroid supplement</p></td>
<td class="Botrule Lrule"><p class="First">Thyroid</p></td>
<td class="Botrule Rrule"><p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> in patients taking digoxin may increase the dose requirements of digoxin.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Sympathomimetics</p></td>
<td class="Botrule Lrule">
<p class="First">Epinephrine</p>
<p>Norepinephrine</p>
<p>Dopamine</p>
</td>
<td class="Botrule Rrule"><p class="First">Can increase the risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Neuromuscular Blocking Agents</p></td>
<td class="Botrule Lrule"><p class="First">Succinylcholine</p></td>
<td class="Botrule Rrule"><p class="First">May cause sudden extrusion of potassium from muscle cells causing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in patients taking digoxin.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Supplements</p></td>
<td class="Botrule Lrule"><p class="First">Calcium</p></td>
<td class="Botrule Rrule"><p class="First">If administered rapidly by intravenous route, can produce serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in digitalized patients.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"> Beta-adrenergic blockers and  calcium channel blockers</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Rrule"><p class="First">Additive effects on AV node conduction can result in <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2a2707bd-774c-4f04-89d1-90301af06cd5"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drug/Laboratory Test Interactions</h2>
<p class="First">Endogenous substances of unknown composition (digoxin-like immunoreactive substances, DLIS) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced. Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason. The measured levels of DLIS (as digoxin equivalents) are usually low (0.2 to 0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic.</p>
<p>In some assays, spironolactone, canrenone and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen, can cause similar interference.</p>
<p>Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines. The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_d2f3a63f-d607-466b-9796-93fd13be7eae"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_55044dcd-0ede-430e-bc53-02e40c9877ec"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fcb990b5-4302-422c-8071-e07526452295"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects. Pregnancy Category C</span></h3>
<p class="First">Digoxin should be given to a pregnant woman only if clearly needed. It is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Animal reproduction studies have not been conducted with digoxin. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_0800ef6c-ea8f-4fff-9b0a-939c831a24b3"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is not enough data from clinical trials to determine the safety and efficacy of digoxin during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_6af098f3-5b02-4ecf-94bf-fdb1f4dcbf7d"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies have shown that digoxin distributes into breast milk, and that the milk-to-serum concentration ratio is approximately 0.6 to 0.9. However, the estimated exposure of a nursing infant to digoxin via breastfeeding is far below the usual infant maintenance dose. Therefore, this amount should have no pharmacologic effect upon the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_462b87b6-03ac-4b4c-beca-d413c4b2abac"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of digoxin in the control of ventricular rate in children with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> in children have not been established.</p>
<p>The safety and effectiveness of digoxin in the treatment of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in children have not been established in adequate and well controlled studies. However, in published literature of children with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of various etiologies (e.g., <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span>, anthracycline toxicity, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>), treatment with digoxin has been associated with improvements in hemodynamic parameters, and in clinical signs and symptoms.</p>
<p>Newborn infants display considerable variability in their tolerance to digoxin. Premature and immature infants are particularly sensitive to the effects of digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_5d5f58db-8a0c-4e0a-b589-a59ddfefd731"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The majority of clinical experience gained with digoxin has been in the elderly population. This experience has not identified differences in response or adverse effects between the elderly and younger patients. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function <span class="Italics">[see <a href="#ID_285cf51f-2424-4646-9efd-60593adc1d23">Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8a9b1193-77e4-4ac5-829c-ef7e75509e0d"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The clearance of digoxin can be primarily correlated with the renal function as indicated by creatinine clearance. Tables 3 and 5 provide the usual daily maintenance dose requirements for digoxin based on creatinine clearance <span class="Italics">[see <a href="#ID_a8a2e598-ceff-4245-ba32-9b085ebb7d60">Dosage and Administration (2.3)</a>]</span>.</p>
<p>Digoxin is primarily excreted by the kidneys; therefore, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> require smaller than usual maintenance doses of digoxin <span class="Italics">[see <a href="#ID_a8a2e598-ceff-4245-ba32-9b085ebb7d60">Dosage and Administration (2.3)</a>]</span>. Because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in patients with normal renal function. If appropriate care is not taken to reduce the dose of digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_74258296-ec77-4cbf-9181-4bc5b13641e7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Plasma digoxin concentrations in patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> generally <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the range of profiles in a group of healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_604bb6a5-690c-4da5-a067-99fa26f61579"></a><a name="section-8.8"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span></h2>
<p class="First">The absorption of digoxin is reduced in some <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> conditions such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_35a982d8-2384-40e2-a524-d998adfa06c8"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fbaf3ebd-423e-4d7c-bb55-6e1f579aef53"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and Symptoms in Adults and Children</h2>
<p class="First">The signs and symptoms of toxicity are generally similar to those described in the <span class="Italics"><a href="#ID_98d8d00e-b938-4dd3-8de9-36d65a4a79ba">Adverse Reactions (6.1)</a></span> but may be more frequent and can be more severe. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> become more frequent with levels above 2 ng/mL. However, in deciding whether a patient’s symptoms are due to digoxin, the clinical state together with serum electrolyte levels and thyroid function are important factors <span class="Italics">[see <a href="#ID_3a08295e-b86d-4944-9d08-904772ea0931">Dosage and Administration (2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_52a6ac2d-761d-4f20-af3f-2d69d4fd5d83"></a><a name="section-9.1.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">The most common signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> that occur in 30% to 70% of patients who are overdosed. Extremely high serum concentrations produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Almost every type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> has been associated with digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and multiple rhythm disturbances in the same patient are common. Peak cardiac effects occur 3 to 6 hours following ingestion and may persist for 24 hours or longer. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> that are considered more characteristic of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> are new-onset Mobitz type 1 A-V block, accelerated <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythms</span>, non-paroxysmal <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> with A-V block and bi-directional <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> is usually fatal.</p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin toxicity</span> is related to serum concentration. As digoxin serum levels increase above 1.2 ng/mL, there is a potential for increase in adverse reactions. Futhermore, lower potassium levels increases the risk for adverse reactions. In adults with heart disease, clinical observations suggest that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 10 mg to 15 mg results in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of half of patients. A dose above 25 mg ingested by an adult without heart disease appeared to be uniformly fatal if no Digoxin Immune Fab (DIGIBIND<span class="Sup">®†</span>, DIGIFAB<span class="Sup">®†</span>) was administered.</p>
<p>Among the extra-cardiac manifestations, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) are very common (up to 80% incidence) and precede cardiac manifestations in approximately half of the patients in most literature reports. Neurologic manifestations (e.g. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, various CNS disturbances), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are very common. Visual manifestations may also occur with aberration in color vision (predominance of yellow green) the most frequent. Neurological and visual symptoms may persist after other signs of toxicity have resolved. In chronic toxicity, non-specific extra-cardiac symptoms, such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, may predominate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fa719660-ac0d-48da-8f52-a4aeb6a0be33"></a><a name="section-9.1.2"></a><p></p>
<h3><span class="Bold">Children</span></h3>
<p class="First">In pediatric patients, signs and symptoms of toxicity can occur during or shortly after the dose of digoxin. Frequent non-cardiac effects are similar to those observed in adults although <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are not seen frequently in infants and small pediatric patients. Other reported manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in older age groups, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> in infants, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> caused by mesenteric artery <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and behavioral disturbances including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic episodes</span>. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> and combinations of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> that occur in adult patients can also occur in pediatric patients although <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> and rapid <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are seen less frequently in pediatric patients. Pediatric patients are more likely to develop A-V conduction disturbances, or <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> in a child treated with digoxin should be considered related to digoxin until otherwise ruled out. In pediatric patients aged 1 to 3 years without heart disease, clinical observations suggest that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 6 mg to 10 mg would result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of half of the patients. In the same population, a dose above 10 mg resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if no Digoxin Immune Fab was administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c7931b48-5ec0-45a3-89f8-af86282214be"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Treatment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf20e703-559f-4b4c-9a26-20d2087d9b25"></a><a name="section-9.2.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Chronic Overdose</span></span></h3>
<p class="First">If there is suspicion of toxicity, discontinue digoxin and place the patient on a cardiac monitor. Correct factors such as electrolyte abnormalities, thyroid dysfunction and concomitant medications <span class="Italics">[see <a href="#ID_2e3812e1-f53c-4969-823e-79519a4c7295">Dosage and Administration (2.5)</a>].</span> Correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> by administering potassium so that serum potassium is maintained between 4 and 5.5 mmol/L. Potassium is usually administered orally, but when correction of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> is urgent and serum potassium concentration is low, potassium may be administered by the intravenous route. Monitor electrocardiogram for any evidence of potassium toxicity (e.g. peaking of T waves) and to observe the effect on the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Avoid potassium salts in patients with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may be treated with Digoxin Immune Fab.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8290d0db-5f49-4eb1-bf6b-4da5ac44b4ca"></a><a name="section-9.2.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span></span></h3>
<p class="First">Patients who have intentionally or accidently ingested massive doses of digoxin should receive activated charcoal orally or by nasogastric tube regardless of the time since ingestion since digoxin recirculates to the intestine by enterohepatic circulation. In addition to cardiac monitoring, temporarily discontinue digoxin until the adverse reaction resolves. Correct factors that may be contributing to the adverse reactions <span class="Italics">[see <a href="#ID_f5264a6d-9a10-4ee0-8e09-9c5286625b36">Warnings and Precautions (5)</a>]</span>. In particular, correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Digoxin is not effectively removed from the body by dialysis because of its large extravascular volume of distribution. Life threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, high degree A-V block, bradyarrhythma, <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span>) or <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> requires administration of Digoxin Immune Fab. Digoxin Immune Fab has been shown to be 80% to 90% effective in reversing signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> caused by digoxin are parasympathetically mediated and respond to atropine. A temporary cardiac pacemaker may also be used. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> may respond to lidocaine or phenytoin. When a large amount of digoxin has been ingested, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be present due to release of potassium from skeletal muscle. In this case, treatment with Digoxin Immune Fab is indicated; an initial treatment with glucose and insulin may be needed if the <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is life threatening. Once the adverse reaction has resolved, therapy with digoxin may be reinstituted following a careful reassessment of dose.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_aba74ed6-505c-4b71-b677-99a4cae277b8"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of <span class="Italics">Digitalis lanata</span>. The term “digitalis? is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence “glycosides?).</p>
<p>Digoxin is described chemically as (3β,5β,12β)-3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribohexopyranosyl) oxy]-12,14-dihydroxy-card-20(22)-enolide. Its molecular formula is C<span class="Sub">41</span>H<span class="Sub">64</span>O<span class="Sub">14</span>, its molecular weight is 780.95, and its structural formula is:</p>
<div class="Figure">
<a name="id583794"></a><img alt="Digoxin Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de7843bb-2cbd-4a76-8cd7-838ed1a12826&amp;name=ea9b834c-9b11-4d79-987f-a8e4ac231ba9-01.jpg">
</div>
<p>Digoxin exists as odorless white crystals that melt with decomposition above 230°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine.</p>
<p>DIGITEK<span class="Sup">®</span> (digoxin tablets, USP) is supplied as 125 mcg (0.125 mg) or 250 mcg (0.25 mg) tablets for oral administration. Each tablet contains the labeled amount of digoxin, USP and the following inactive ingredients: corn starch, croscarmellose sodium, lactose anhydrous, lactose hydrous impalpable, microcrystalline cellulose, pregelatinized starch (corn), silicon dioxide and stearic acid. In addition, the 125 mcg (0.125 mg) tablet contains D&amp;C Yellow No. 10 Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_67aa1766-b6f3-4630-a11e-103d0e4ba6a6"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_8da770a5-7aa8-4a81-8107-ddc5ed13893f"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,? is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin </p>
<dl>
<dt>•</dt>
<dd>causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity and reduced conduction velocity.</dd>
<dt>•</dt>
<dd>indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sinoatrial (SA) and atrioventricular (AV) nodes.</dd>
<dt>•</dt>
<dd>reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines.</dd>
<dt>•</dt>
<dd>increases baroreceptor sensitization, with consequent increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increment in mean arterial pressure.</dd>
<dt>•</dt>
<dd>increases (at higher concentrations) sympathetic outflow from the central nervous system (CNS) to both cardiac and peripheral sympathetic nerves.</dd>
<dt>•</dt>
<dd>allows (at higher concentrations) progressive efflux of intracellular potassium, with consequent increase in serum potassium levels.</dd>
</dl>
<p>The cardiologic consequences of these direct and indirect effects are an increase in the force and velocity of myocardial systolic contraction (positive inotropic action), a slowing of the heart rate (negative chronotropic effect), decreased conduction velocity through the AV node, and a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_8328096c-c045-4eb4-ab5d-b25faaf518bd"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The times to onset of pharmacologic effect and to peak effect of preparations of digoxin are shown in Table 7.</p>
<a name="_RefID0ERCAI"></a><table width="100%">
<caption><span>Table 7. Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of DIGITEK<span class="Sup">®</span> (digoxin tablets)</span></caption>
<col width="36%">
<col width="34%">
<col width="30%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Documented for ventricular response rate in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, inotropic effects and electrocardiographic changes.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Depending upon rate of infusion.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Product</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time to Onset of Effect</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time to Peak Effect</span><a href="#footnote-9" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 to 2 hours</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 to 6 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Digoxin Injection/IV</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 to 30 minutes<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 to 4 hours</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_723a6148-c6e0-444d-8016-1bc65cb3f507"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold">Hemodynamic Effects</span></h3>
<p class="First">Short and long term therapy with the drug increases <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and lowers pulmonary artery pressure, pulmonary capillary wedge pressure and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. These hemodynamic effects are accompanied by an increase in the left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and a decrease in end-systolic and end-diastolic dimensions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5598796f-2348-4db2-97ea-a3d0b4a93d4c"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold">ECG Changes</span></h3>
<p class="First">The use of therapeutic doses of digoxin may cause prolongation of the PR interval and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the ST segment on the electrocardiogram. Digoxin may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects are not indicative of toxicity. Digoxin does not significantly reduce heart rate during exercise. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_78bc1561-facf-4be6-a2f0-83af1220b806"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Note: The following data are from studies performed in adults, unless otherwise stated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dc045752-d2b2-4dba-b83f-4b1dcd54b3f0"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Following oral administration, peak serum concentrations of digoxin occur at 1 to 3 hours. Absorption of digoxin from digoxin tablets has been demonstrated to be 60% to 80% complete compared to an identical intravenous dose of digoxin (absolute bioavailability). When digoxin tablets are taken after meals, the rate of absorption is slowed, but the total amount of digoxin absorbed is usually unchanged. When taken with meals high in bran fiber, however, the amount absorbed from an oral dose may be reduced. Comparisons of the systemic availability and equivalent doses for oral preparations of digoxin are shown in <span class="Italics"><a href="#ID_a0d51621-c5d4-4c80-a11f-79aa449f4376">Dosage and Administration (2.6)</a></span>.</p>
<p>Digoxin is a substrate for P-glycoprotein. As an efflux protein on the apical membrane of enterocytes, P-glycoprotein may limit the absorption of digoxin.</p>
<p>In some patients, orally administered digoxin is converted to inactive reduction products (e.g., dihydrodigoxin) by colonic bacteria in the gut. Data suggest that 1 in 10 patients treated with digoxin tablets, colonic bacteria will degrade 40% or more of the ingested dose. As a result, certain antibiotics may increase the absorption of digoxin in such patients. Although inactivation of these bacteria by antibiotics is rapid, the serum digoxin concentration will rise at a rate consistent with the elimination half-life of digoxin. Serum digoxin concentration relates to the extent of bacterial inactivation, and may be as much as doubled in some cases <span class="Italics">[see <a href="#ID_369964ad-4efa-40b5-87cf-732c12221551">Drug Interactions (7.2)</a>].</span></p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndromes</span> (e.g., short bowel syndrome, celiac <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">sprue</span>, jejunoileal bypass) may have a reduced ability to absorb orally administered digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_81fb9fc3-a5ca-4c4b-a539-545cb600e7f2"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">Following drug administration, a 6- to 8-hour tissue distribution phase is observed. This is followed by a much more gradual decline in the serum concentration of the drug, which is dependent on the elimination of digoxin from the body. The peak height and slope of the early portion (absorption/distribution phases) of the serum concentration-time curve are dependent upon the route of administration and the absorption characteristics of the formulation. Clinical evidence indicates that the early high serum concentrations do not reflect the concentration of digoxin at its site of action, but that with chronic use, the steady-state post-distribution serum concentrations are in equilibrium with tissue concentrations and correlate with pharmacologic effects. In individual patients, these post-distribution serum concentrations may be useful in evaluating therapeutic and toxic effects <span class="Italics">[see <a href="#ID_285cf51f-2424-4646-9efd-60593adc1d23">Dosage and Administration (2.1)</a>]</span>.</p>
<p>Digoxin is concentrated in tissues and therefore has a large apparent volume of distribution (approximately 475 to 500 L). Digoxin crosses both the blood-brain barrier and the placenta. At delivery, the serum digoxin concentration in the newborn is similar to the serum concentration in the mother. Approximately 25% of digoxin in the plasma is bound to protein. Serum digoxin concentrations are not significantly altered by large changes in fat tissue weight, so that its distribution space correlates best with lean (i.e., ideal) body weight, not total body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6be19174-ade2-4d23-b53d-3ac67d3b7310"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Only a small percentage (13%) of a dose of digoxin is metabolized in healthy volunteers. The urinary metabolites, which include dihydrodigoxin, digoxigenin bisdigitoxoside, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation and conjugation. The metabolism of digoxin is not dependent upon the cytochrome P-450 system, and digoxin is not known to induce or inhibit the cytochrome P-450 system.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3c0d27c1-d52f-44ba-88df-f72a94aa2183"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold">Excretion</span></h3>
<p class="First">Elimination of digoxin follows first-order kinetics (that is, the quantity of digoxin eliminated at any time is proportional to the total body content). Following intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine. Renal excretion of digoxin is proportional to creatinine clearance and is largely independent of urine flow. In healthy volunteers with normal renal function, digoxin has a half-life of 1.5 to 2 days. The half-life in anuric patients is prolonged to 3.5 to 5 days. Digoxin is not effectively removed from the body by dialysis, exchange transfusion or during cardiopulmonary bypass because most of the drug is bound to extravascular tissues.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a02190d0-ea82-46d2-8f06-0c8523959b76"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61d3fd6e-0faf-46f8-8e3e-6cf0c8c98d9f"></a><a name="section-11.3.5.1"></a><p></p>
<h4><span class="Bold">Geriatrics</span></h4>
<p class="First">Because of age-related declines in renal function, elderly patients would be expected to eliminate digoxin more slowly than younger subjects. Elderly patients may also exhibit a lower volume of distribution of digoxin due to age-related loss of lean <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>. Thus, the dosage of digoxin should be carefully selected and monitored in elderly patients <span class="Italics">[see <a href="#ID_5d5f58db-8a0c-4e0a-b589-a59ddfefd731">Use in Specific Populations (8.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fd50adf9-9211-432a-b7e0-e67dc1d6cc12"></a><a name="section-11.3.5.2"></a><p></p>
<h4><span class="Bold">Gender </span></h4>
<p class="First">In a study of 184 patients, the clearance of digoxin was 12% lower in female than in male patients. This difference is not likely to be clinically important.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36b8e0b1-3753-4858-a21d-75319422f09f"></a><a name="section-11.3.5.3"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h4>
<p class="First">Because only a small percentage (approximately 13%) of a dose of digoxin undergoes metabolism, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> would not be expected to significantly alter the pharmacokinetics of digoxin. In a small study, plasma digoxin concentration profiles in patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> generally fell within the range of profiles in a group of healthy subjects. No dosage adjustments are recommended for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; however, serum digoxin concentrations should be used as appropriate to help guide dosing in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b0e66361-d77e-494f-b655-9e7fcfdd8987"></a><a name="section-11.3.5.4"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></h4>
<p class="First">Since the clearance of digoxin correlates with creatinine clearance, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> generally demonstrate prolonged digoxin elimination half-lives and greater exposures to digoxin. Therefore, titrate carefully in these patients based on clinical response, and based on monitoring of serum digoxin concentrations, as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_816c9cf6-efe8-4356-b638-c9a88a2d3f1a"></a><a name="section-11.3.5.5"></a><p></p>
<h4><span class="Bold">Race </span></h4>
<p class="First">The impact of race differences on digoxin pharmacokinetics has not been formally studied. Because digoxin is primarily eliminated as unchanged drug via the kidney and because there are no important differences in creatinine clearance among races, pharmacokinetic differences due to race are not expected.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_23ad37e8-0e6c-407a-b02c-a5afd6743650"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold">Drug-Drug Interactions</span></h3>
<p class="First">Based on literature reports no significant changes in digoxin exposure were reported when digoxin was coadministered with the following drugs:</p>
<p>alfuzosin, aliskiren, amlodipine, aprepitant, argatroban, aspirin, atorvastatin, benazepril, bisoprolol, black cohosh, bosentan, candesartan, citalopram, clopidogrel, colesevelam, dipyridamole, disopyramide, donepezil, doxazosin, dutasteride, echinacea, enalapril, eprosartan, ertapenem, escitalopram, esmolol, ezetimibe, famciclovir, felodipine, finasteride, flecainide, fluvastatin, fondaparinux, galantamine, gemifloxacin, grapefruit juice, irbesartan, isradipine, ketorolac, levetiracetam, levofloxacin, lisinopril, losartan, lovastatin, meloxicam, mexilitine, midazolam, milk thistle, moexipril, montelukast, moxifloxacin, mycophenolate, nateglinide, nesiritide, nicardipine, nisoldipine, olmesartan, orlistat, pantoprazole, paroxetine,perindopril, pioglitazone, pravastatin, prazosin, procainamide, quinapril, raloxifene, ramipril, repaglinide, rivastigmine, rofecoxib, ropinirole, rosiglitazone, rosuvastatin, sertraline, sevelamer, simvastatin, sirolimus, solifenacin, tamsulosin, tegaserod, terbinafine, tiagabine, ticlopidine, tigecycline, topiramate, torsemide, tramadol, trandolapril, triamterene, trospium, trovafloxacin, valacyclovir, valsartan, varenicline, voriconazole, zaleplon, zolpidem</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_11345d2f-a2b0-4823-bfed-7ea337b8feb0"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_29808838-7fec-4e78-ab3b-222a645381ae"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Digoxin showed no genotoxic potential in <span class="Italics">in vitro </span>studies (Ames test and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>). No data are available on the carcinogenic potential of digoxin, nor have studies been conducted to assess its potential to affect fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_e21d98c4-ad62-4847-8e13-6bf4508f9a0a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_63bb3b7f-2e4e-4ab9-8fc9-3adec10f3c86"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Two 12-week, double-blind, placebo-controlled studies enrolled 178 (RADIANCE trial) and 88 (PROVED trial) adult patients with NYHA class II or III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> previously treated with oral digoxin, a diuretic, and an ACE inhibitor (RADIANCE only) and randomized them to placebo or treatment with digoxin. Both trials demonstrated better preservation of exercise capacity in patients randomized to digoxin. Continued treatment with digoxin reduced the risk of developing worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, as evidenced by <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care and the need for concomitant <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_065fe928-db48-4175-b09e-fb0bfc8e9b64"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Bold">DIG Trial of Digoxin in Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h3>
<p class="First">The Digitalis Investigation Group (DIG) main trial was a 37-week, multicenter, randomized, double-blind mortality study comparing digoxin to placebo in 6,800 adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤ 0.45. At randomization, 67% were NYHA class I or II, 71% had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of ischemic etiology, 44% had been receiving digoxin, and most were receiving a concomitant ACE inhibitor (94%) and diuretics (82%). As in the smaller trials described above, patients who had been receiving open-label digoxin were withdrawn from this treatment before randomization. Randomization to digoxin was again associated with a significant reduction in the incidence of hospitalization, whether scored as number of hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (relative risk 75%), risk of having at least one such hospitalization during the trial (RR 72%), or number of hospitalizations for any cause (RR 94%). On the other hand, randomization to digoxin had no apparent effect on mortality (RR 99%, with confidence limits of 91% to 107%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6cee8511-a07c-4e93-b768-3bfd95b0709f"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Chronic Atrial Fibrillation</span></h2>
<p class="First">Digoxin has also been studied as a means of controlling the ventricular response to <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> in adults. Digoxin reduced the resting heart rate, but not the heart rate during exercise.</p>
<p>In three different randomized, double-blind trials that included a total of 315 adult patients, digoxin was compared to placebo for the conversion of recent-onset <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to sinus rhythm. Conversion was equally likely, and equally rapid, in the digoxin and placebo groups. In a randomized 120-patient trial comparing digoxin, sotalol and amiodarone, patients randomized to digoxin had the lowest incidence of conversion to sinus rhythm, and the least satisfactory rate control when conversion did not occur.</p>
<p>In at least one study, digoxin was studied as a means of delaying reversion to <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> in adult patients with frequent recurrence of this <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. This was a randomized, double-blind, 43-patient crossover study. Digoxin increased the mean time between symptomatic recurrent episodes by 54%, but had no effect on the frequency of fibrillatory episodes seen during continuous electrocardiographic monitoring. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_f2ab2902-d1d9-422c-bc18-2cbf9a2823fc"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DIGITEK<span class="Sup">®</span> (digoxin tablets, USP) is available containing 125 mcg (0.125 mg) or 250 mcg (0.25 mg) of digoxin, USP.</p>
<p>The 125 mcg (0.125 mg) tablets are yellow round, scored, slope-faced tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">145</span> below the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 42292-003-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 tablets each).</p>
<p>The 250 mcg (0.25 mg) tablets are white round, scored, slope-faced tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">147</span> below the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 42292-002-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 tablets each).</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span><br><span class="Bold">Store in a dry place. Protect from light.</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_5ffda8e2-e044-473d-aa22-8504ac7560ff"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise patients that digoxin is a cardiac glycoside used to treat <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and heart <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. </dd>
<dt>•</dt>
<dd>Instruct patients to take this medication as directed by their physician. </dd>
<dt>•</dt>
<dd>Advise patients that many drugs can interact with digoxin. Instruct patients to inform their doctor and pharmacist if they are taking any over the counter medications, including herbal medication, or are started on a new prescription.</dd>
<dt>•</dt>
<dd>Advise patients that blood tests will be necessary to ensure that their digoxin dose is appropriate for them.</dd>
<dt>•</dt>
<dd>Advise patients to contact their doctor or a healthcare professional if they experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, green-yellow color disturbances, halo effect) as these could be signs that the dose of digoxin may be too high.</dd>
<dt>•</dt>
<dd>Advise parents or caregivers that the symptoms of having too high digoxin doses may be difficult to recognize in infants and pediatric patients. Symptoms such as <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> in infants, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and behavioral disturbances may be indications of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>.</dd>
<dt>•</dt>
<dd>Suggest to the patient to monitor and record their heart rate and blood pressure daily.</dd>
<dt>•</dt>
<dd>Instruct women of childbearing potential who become or are planning to become pregnant to consult a physician prior to initiation or continuing therapy with digoxin.</dd>
</dl>
<p class="First">† The brands listed are trademarks of their respective owners.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV  26505  U.S.A.</p>
<p>Distributed by:<br><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL 61103 U.S.A.</p>
<p>S-12174<br>3/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0ccfc1a6-754c-4ae9-9558-902d5287e917"></a><a name="section-16"></a><p></p>
<h1>       </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 125 mcg (0.125 mg)</span></p>
<p>NDC 42292-003-20</p>
<p><span class="Bold"><span class="Italics">DIGITEK<span class="Sup">®</span></span></span><br><span class="Bold">(digoxin tablets, USP)</span><br><span class="Bold">125 mcg</span><br><span class="Bold">(0.125 mg)</span></p>
<p>100 Tablets (10 x 10)</p>
<p>Each tablet contains digoxin USP,<br>125 mcg (0.125 mg).</p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span><br><span class="Bold">Store in a dry place. Protect</span><span class="Bold">from light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-12173</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id1576629043"></a><img alt="Digitek (digoxin tablets, USP) 125 mcg (0.125 mg) Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de7843bb-2cbd-4a76-8cd7-838ed1a12826&amp;name=image-01.jpg">
</div>
<div class="Figure">
<a name="id-1503113876"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de7843bb-2cbd-4a76-8cd7-838ed1a12826&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f9a3dddd-0b34-45aa-9259-1d456764d05a"></a><a name="section-17"></a><p></p>
<h1>       </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 250 mcg (0.25 mg)</span></p>
<p>NDC 42292-002-20</p>
<p><span class="Bold"><span class="Italics">DIGITEK<span class="Sup">®</span></span></span><br><span class="Bold">(digoxin tablets, USP)</span><br><span class="Bold">250 mcg</span><br><span class="Bold">(0.25 mg)</span></p>
<p>100 Tablets (10 x1 0)</p>
<p>Each tablet contains digoxin USP,<br>250 mcg (0.25 mg).</p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span><br><span class="Bold">Store in a dry place. Protect</span><span class="Bold">from light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-12172</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id-1837295979"></a><img alt="Digitek (digoxin tablets, USP) 250 mcg (0.25 mg) Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de7843bb-2cbd-4a76-8cd7-838ed1a12826&amp;name=image-03.jpg">
</div>
<div class="Figure">
<a name="id-1865127110"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de7843bb-2cbd-4a76-8cd7-838ed1a12826&amp;name=image-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIGITEK 		
					</strong><br><span class="contentTableReg">digoxin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42292-003(NDC:0378-6155)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIGOXIN</strong> (DIGOXIN) </td>
<td class="formItem">DIGOXIN</td>
<td class="formItem">0.125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;145</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42292-003-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42292-003-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040282</td>
<td class="formItem">06/18/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIGITEK 		
					</strong><br><span class="contentTableReg">digoxin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42292-002(NDC:0378-6156)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIGOXIN</strong> (DIGOXIN) </td>
<td class="formItem">DIGOXIN</td>
<td class="formItem">0.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;147</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42292-002-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42292-002-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040282</td>
<td class="formItem">06/18/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>de7843bb-2cbd-4a76-8cd7-838ed1a12826</div>
<div>Set id: de7843bb-2cbd-4a76-8cd7-838ed1a12826</div>
<div>Version: 1</div>
<div>Effective Time: 20150306</div>
</div>
</div> <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
